← All trials
NCT01367314
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2009
- Primary completion
- May 1, 2010
- Completion date
- Dec 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 129
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- NovaBay PharmaceuticalsLead sponsor
- Hospital Infantil Dr. Robert Reid CabralOverall official - principal investigator
- Novum Pharmaceutical Research ServicesCollaborator
- NovaBay PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.